Acadia Pharmaceuticals to Present DAYBUE™ (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual MeetingBusiness Wire • 04/20/23
Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett SyndromeBusiness Wire • 04/17/23
Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare ConferenceBusiness Wire • 04/11/23
Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's TypeBusiness Wire • 04/03/23
Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's TypeBusiness Wire • 04/03/23
Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer'sBusiness Wire • 03/22/23
Strength Seen in Acadia (ACAD): Can Its 5.0% Jump Turn into More Strength?Zacks Investment Research • 03/15/23
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and OlderBusiness Wire • 03/11/23
ACADIA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACADBusiness Wire • 03/04/23
Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/27/23
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating OverviewBusiness Wire • 02/27/23
Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 02/20/23
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023Business Wire • 02/14/23
Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and DevelopmentBusiness Wire • 01/09/23
Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson's Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical AntipsychoticsBusiness Wire • 01/03/23
Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023Business Wire • 12/21/22